Agios Pharmaceuticals Q3 net loss narrows 37% year over year to $65.05 million

PUBT · 1d ago
Agios Pharmaceuticals Q3 net loss narrows 37% year over year to $65.05 million
  • Agios Pharmaceuticals’ third-quarter 2026 net loss narrowed 37% year over year to $65.05 million.
  • Product revenue rose year over year to $55.39 million, supported by the U.S. launch of AQVESME in thalassemia.
  • Cash, cash equivalents and marketable securities totaled $907.02 million at September 30, 2026.
  • The FDA extended its mitapivat sickle cell disease review deadline three months to February 1, 2027; Agios remains launch-ready.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050630PRIMZONEFULLFEED9870817) on November 05, 2026, and is solely responsible for the information contained therein.